实时液体活检联合TNM分期指导鼻咽癌诱导化疗周期:开发与验证研究
该回顾性研究纳入中心1的794例和中心2的448例局部晚期鼻咽癌患者,基于第2周期后血浆EBV-DNA状态和分期构建策略指导诱导化疗周期选择。
要点
- 第2周期后EBV-DNA可检测的IVA期患者,3周期IC较2周期改善5年FFS。
- III期或第2周期后EBV-DNA不可检测者,第3周期IC未见明确获益。
- 该策略在外部验证队列中得到确认。
核心结论
- 第2周期后EBV-DNA可检测的IVA期局部晚期鼻咽癌患者可从第3周期诱导化疗中获益。
- III期或第2周期后EBV-DNA不可检测的患者,第3周期诱导化疗未见明确获益。
研究设计与样本
- 回顾性研究,训练队列来自中山大学肿瘤防治中心(中心1)的794例患者,外部验证队列来自福建省肿瘤医院(中心2)的448例患者。
- 所有患者接受2至3周期诱导化疗联合(放)化疗,并在第2周期后检测血浆EBV-DNA。
主要发现
- 训练队列中,递归分割分析将患者分为3个不同预后组。
- 上述结果在外部验证队列中得到确认。
临床怎么用
- 对于IVA期且第2周期后EBV-DNA可检测的局部晚期鼻咽癌患者,可考虑给予第3周期诱导化疗。
- 对于III期或第2周期后EBV-DNA不可检测的患者,第3周期诱导化疗未见明确获益,应个体化决策。
局限性
- 本研究为回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The optimal number of induction chemotherapy (IC) cycles for locally advanced nasopharyngeal carcinoma (LA-NPC) is uncertain. This retrospective study proposes and validates a strategy combining clinical staging with post-cycle-2 plasma Epstein-Barr virus (EBV)-DNA status to guide IC cycle selection. METHODS AND MATERIALS: Patients with LA-NPC from Sun Yat-sen University Cancer Center (center 1) formed the training cohort, and those from Fujian Cancer Hospital (center 2) comprised the external validation cohort. All received 2 to 3 IC cycles plus (chemo)radiation therapy, with plasma EBV-DNA measured after cycle-2 (post-IC2-EBV-DNA). Failure-free survival (FFS) was compared between 2- versus 3-cycle IC and stratified by recursive partitioning analysis. RESULTS: The training and validation cohorts comprised 794 and 448 patients, evenly divided between 3- and 2-cycle IC. In the training cohort, recursive partitioning analysis stratified patients into 3 distinct prognostic groups. Among the low-risk group (undetectable post-IC2-EBV-DNA), FFS was comparable between the 3- and 2-cycle IC (83.8% vs 87.3%, P = .647). In the detectable cohort, patients with stage IVA disease (high-risk group) who received 3-cycle IC had improved 5-year FFS versus 2-cycle (74.0% vs 56.8%; P = .013), whereas no difference was observed in stage III (intermediate-risk group) (75.9% vs 83.1%; P = .269). Findings were confirmed in the external validation cohort. CONCLUSIONS: This retrospective study indicates that patients with stage IVA LA-NPC with detectable EBV-DNA after 2 IC cycles benefit from a third cycle, whereas no clear benefit of a third cycle is observed in patients with stage III or in those with undetectable post-IC2-EBV-DNA.
引用
- Ji P, Shen J, He D, et al. Combined Real-time Liquid Biopsy With TNM Stage to Guide Induction Chemotherapy Cycles in Nasopharyngeal Carcinoma: A Development and Validation Study. Int J Radiat Oncol Biol Phys. 2026. PMID: 41831793. doi:10.1016/j.ijrobp.2026.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。